Stock Market Reviews

SCYX (SCYNEXIS, Inc.) News

Get the latest news, insights, and market updates on SCYX (SCYNEXIS, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
  SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company’s Board of Directors. “Eric’s decades of financial, transactional and operational experience will make an immediate impact to CERo’s board of directors,” said Chris Ehrlich, Company Chairman and Chief Execut
  Feb 17, 2026 - $SCYX
• SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
  This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutionsJERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247
  Jan 28, 2026 - $SCYX
• SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
  The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration
  Jan 21, 2026 - $SCYX
• SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
  JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the require
  Dec 22, 2025 - $SCYX
• SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
  GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the
  Nov 19, 2025 - $SCYX
• Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
  Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fungerps).Next-generation fungerps, in preclinical stages of development, are targeted to have enhanced pharmacological properties to treat fungal infections where current therapies are limited or not effective, while maintaining broad spectrum of activity against
  Nov 17, 2025 - $SCYX
• Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation
  We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
  Nov 10, 2025 - $SCYX
• SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate the study.Following the positive SAD/MAD data results announced in September for SCY-247, its second-generation fungerp, the Company expects to initiate a Phase 1 study with the IV formulation and a Phase 2 study for the treatment of invasive candidiasis. The Co
  Nov 5, 2025 - $SCYX
• Scynexis: Q3 Earnings Snapshot
  JERSEY CITY, N.J. (AP) — Scynexis Inc. SCYX) on Wednesday reported a loss of $8.6 million in its third quarter. The Jersey City, New Jersey-based company said it had a loss of 17 cents per share.
  Nov 5, 2025 - $SCYX
• SCYNEXIS Reports Positive Phase 1 Results for Second-Generation Antifungal SCY-247
  SCYNEXIS Inc. (NASDAQ:SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS announced positive results from a Phase 1 clinical study evaluating SCY-247, its second-generation triterpenoid antifungal compound. The candidate is being developed for the treatment and prevention of invasive fungal infections to provide the therapeutic advantages […]
  Oct 24, 2025 - $SCYX